Decision Resources, Inc., announces a new study, Emerging Therapies in Chronic Pain, that evaluates the opportunities awaiting new drugs in this marketplace. Prescription drugs to treat chronic and severe pain from cancer, low-back injury, and osteoarthritis (OA) totaled an estimated $4.8 billion in 2000 in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We expect this number to surpass $7 billion by 2010, primarily as a result of the introduction of novel pain medications.

(Photo: )

Emerging Therapies in Chronic Pain reviews and evaluates several novel classes of pain therapies that have been the subject of clinical and preclinical research activity. Of the hundreds of investigational agents under study for pain control, the second-generation cyclooxygenase-2 (COX-2) inhibitors hold the greatest commercial promise, despite offering only incremental clinical advantages over current therapies. The recent success of the COX-2 inhibitors in the large and underserved market for pain therapies exemplifies the significant commercial opportunity for novel agents in development for this indication. Selective COX-2 inhibitors have quickly overtaken traditional NSAIDs in the treatment of OA in the United States, the largest market for these novel drugs. COX-2 inhibitors are also penetrating the low-back and cancer pain markets but less dramatically because they are not formally approved for use in these indications.

We forecast continued uptake of COX-2 inhibitors in each of the three pain indications under study-even in the absence of formal approval for use in cancer and low-back pain-and in all market regions, with their most dramatic success continuing to be in the approved indication of OA and in the United States. The success of the COX-2 inhibitor class through the 2000-2010 decade will be bolstered by the launch of new agents in the class-second-generation COX-2 inhibitors-that offer even greater selectivity for the COX-2 isoform.

Emerging Therapies in Chronic Pain offers invaluable market intelligence for pharmaceutical companies competing in the chronic pain drug market. This study is part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,

Chemotherapy Will Assume an Important Role in Prostate Cancer Treatment, According to a Decision Resources Study

View Now